Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany
Year: 2026
Type: dataset
Abstract: Resmetirom is the first approved pharmacological treatment for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-advanced fibrosis (F2–F3). We estimated its value-based annual price in China, the United Kingdom, France, and Germany from the health-care payer perspective. We developed an annual-cycle Markov model for eligible F2-F3 patients receiving standard of care (SoC) or resmetirom plus SoC. Country-specific epidemiology, costs, and willingness-to-pay (WTP) thresholds were applied. Value-based pricing (VBP) was the annual price at which the incremental cost-effectiveness ratio (ICER) equaled the country-specific WTP threshold per quality-adjusted life-year (QALY). Analyses included ICERs at the current US price and probabilistic sensitivity analysis. Resmetirom increased life-years (LYs) by 0.30, 0.71, 0.96, and 0.80 in China, the UK, France, and Germany, with QALY gains of 0.47, 0.96, 1.28, and 1.07. Estimated VBPs were US$3,573, US$6,487, US$9,334, and US$10,656, respectively. At the current US annual price, ICERs exceeded country-specific WTP thresholds in all settings. Price reductions toward country-specific VBPs would be required for resmetirom to be cost-effective in these publicly financed health systems. Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common chronic liver disease that can progress to liver fibrosis, cirrhosis, liver cancer, and liver-related death. Resmetirom is the first approved drug for adults with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-advanced fibrosis, but its current United States annual price is high. This study estimated the annual price at which resmetirom would provide good value for money in China, the United Kingdom, France, and Germany. We used a disease-progression model comparing standard care with resmetirom plus standard care. Resmetirom improved health outcomes in all four countries. However, the estimated value-based annual prices were much lower than the current US price: US$3,573 in China, US$6,487 in the United Kingdom, US$9,334 in France, and US$10,656 in Germany. These findings suggest that substantial price reductions would be needed for resmetirom to be cost-effective in these publicly financed health systems.
Source: Figshare
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Keywords: resmetirom, non-alcoholic fatty liver disease, liver fibrosis, value-based pricing, cost-effectiveness, willingness-to-pay threshold, Markov model, quality-adjusted life years, drug pricing, China, United Kingdom, France, Germany, publicly funded health systems, disease progression model, nonalcoholic steatohepatitis
Open Access status: green
OpenAlex ID: W7202242587
